Nervica 25/Nervica 75/Nervica 150

Peripheral & central neuropathic pain, & generalized anxiety disorder (GAD) in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalization.

150-600 mg daily in 2 or 3 divided doses. Neuropathic pain Initially 150 mg daily in 2 or 3 divided doses, may be increased to 300 mg daily after an interval of 3-7 days, & if needed to max of 600 mg daily after an additional 7-day interval. Epilepsy Initially 150 mg daily in 2 or 3 divided doses, may be increased to 300 mg daily after 1 wk. Max: 600 mg daily may be achieved after an additional wk. GAD Initially 150 mg daily, may be increased to 300 mg daily after 1 wk, & following an additional wk, may be increased to 450 mg daily. Max: 600 mg daily may be achieved after an additional wk. Renal impairment CrCl ≥60 mL/min Initially 150 mg daily in 2 or 3 divided doses. Max: 600 mg daily, ≥30-<60 mL/min Initially 75 mg daily in 2 or 3 divided doses. Max: 300 mg daily, ≥15-<30 mL/min Initially 25-50 mg once daily or in 2 divided doses. Max: 150 mg daily, <15 mL/min Initially 25 mg once daily. Max: 75 mg daily. Supplementary dose following hemodialysis: Initially 25 mg daily as single dose. Max: 100 mg daily.

May be taken with or without food.

Hypersensitivity.

Discontinue use if symptoms of angioedema (eg, facial, perioral, or upper airway swelling) occur. Diabetic patients who gain wt during treatment may need to adjust hypoglycemic medicinal products. Dizziness & somnolence [which could increase occurrence of accidental injury (fall) in the elderly], loss of consciousness, confusion & mental impairment; vision-related effects; CHF; encephalopathy. Insufficient data on w/drawal of concomitant antiepileptic medicinal products once seizure control w/ pregabalin in the add-on situation has been reached. W/drawal symptoms after short & long-term treatment. Increased incidence of adverse reactions especially somnolence in treatment of central neuropathic pain due to spinal cord injury. Discontinuation should be gradually done over min of 1 wk. Monitor patients for signs of suicidal ideation & behaviors. Exercise caution in patients w/ history of substance abuse & monitor for symptoms of misuse, abuse or dependence. Reduced lower GI tract function w/ medications that have potential to produce constipation eg, opioid analgesics. Risk of CNS depression w/ opioids. Renal failure. May have minor or moderate influence on ability to drive & use machines. Women of childbearing potential should use effective contraception during treatment. Pregnancy & lactation. Safety & efficacy in childn <12 yr & adolescents 12-17 yr have not been established. Elderly.

Dizziness, somnolence, headache. Nasopharyngitis; increased appetite; euphoric mood, confusion, irritability, disorientation, insomnia, decreased libido; ataxia, abnormal coordination, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paresthesia, hypoesthesia, sedation, balance disorder, lethargy; blurred vision, diplopia; vertigo; vomiting, nausea, constipation, diarrhea, flatulence, abdominal distension, dry mouth; muscle cramp, arthralgia, back pain, pain in limb, cervical spasm; erectile dysfunction; peripheral edema, edema, abnormal gait, fall, drunk & abnormal feeling, fatigue; increased wt.

May potentiate effects of ethanol & lorazepam. Reports of resp failure & coma w/ other CNS depressants. Additive effect in the impairment of cognitive & gross motor function by oxycodone.

Anticonvulsants / Drugs for Neuropathic Pain

N02BF02 - pregabalin ; Belongs to the class of gabapentinoids. Used to relieve pain and other conditions.

Rx